Healthcare Providers and Services
Company Overview of Hackensack University Medical Center
Hackensack University Medical Center operates as a nonprofit teaching and research hospital that provides inpatient and outpatient services in New Jersey. The company offers emergency services, such as pediatric emergency, trauma, emergency preparedness, EM residency, family-centered care, mobile acute care hospital, mobile intensive care unit, and observation unit; and hospital services, including bioethics, communications and public relations, health information, information and guest services, medical physics, nutrition and food management, occupational therapy, pastoral care, pathology, inpatient and outpatient pharmacy, physical therapy, radiology, security, social service, speech thera...
30 Prospect Avenue
Hackensack, NJ 07601
Founded in 1888
Key Executives for Hackensack University Medical Center
Chief Executive Officer, President, Member of Board of Governors, Member of Advisory Board, Ex-officio Member of Finance Committee, Ex-officio Member of Audit & Compliance Committee, Ex-officio Member of Board Development Committee and Ex-officio Member of Governance Committee
Chief Financial Officer, Executive Vice President and Member of Audit & Compliance Committee
Chief Executive Officer of Pascack Valley
Executive Vice President of Patient Care Division and Chief Nursing Officer
Chairman of Orthopedic Surgery Department
Compensation as of Fiscal Year 2016.
Hackensack University Medical Center Key Developments
Hackensack University Medical Center Announces Clinical Trial Suggests Value of Venetoclax Combination Therapy in Patients with B-Cell Non-Hodgkin Lymphoma
Jun 6 16
A new global multi-center study co-authored by John Theurer Cancer Center (JTCC) at Hackensack University Medical Center researchers and presented here on June 6, 2016 at the American Society of Clinical Oncology (ASCO) annual meeting concludes that venetoclax, a selective, potent oral BCL-2 inhibitor with activity in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) in combination with standard therapeutic regimens, was well-tolerated and provides evidence of its potential therapeutic value in this patient population. The open-label, dose-finding trial, "Phase 1b study of Venetoclax Plus R- or G-CHOP in Patients with B-cell Non-Hodgkin Lymphoma," (Abstract No. 7566, Poster no. 122) evaluated a regimen used commonly in the treatment of NHL known as CHOP (Cyclophosphamide, Hydroxydaunomycin, Oncovin, Prednisone) in combination with either rituximab or obinutuzumab, to which venetoclax was added. Previous studies in NHL xenograft models have shown that venetoclax may enhance efficacy of rituximab plus CHOP (R-CHOP), or obinutuzumab plus CHOP (G-CHOP) therapies. This study sought to assess safety and tolerability of venetoclax in combination with R-CHOP or G-CHOP in patients with no more than one previous course of therapy and to determine the maximum tolerable dose (MTD) and define appropriate dose of venetoclax for a subsequent Phase 2 study and assess optimal therapeutic benefit. Primary outcome measures for the study are incidence of dose-limiting toxicities and complete response (CR) as defined by PET/CT scan and bone marrow examination. The expected study completion date is April 2018. As of November 30, 2015, 46 patients were enrolled in four cohorts and divided into two arms – rituximab plus CHOP (Arm A) and obinutuzumab plus CHOP (Arm B). Patients in cohort 1 received venetoclax 200-800 mg on cycle 1, day 4, and then daily for 8 cycles. In cohorts 2-4, patients received venetoclax on cycle 1, days 4-10 and cycles 2-8, days 1-10. CHOP was administered for six 21-day cycles. Rituximab was given on day 1 of cycles 1-8 (Arm A), while obinutuzumab was given on days 1, 8 and 15 of cycle 1 and day 1 of cycles 2-8 (Arm B). The most grade common adverse events were nausea (48%), fatigue (41%), and diarrhea (41%), and the most common grade 3-4 adverse events were neutropenia (37%) and febrile neutropenia (26%). Researchers determined that venetoclax combined with R- or G-CHOP was well-tolerated, and concluded that the appropriate dose for a Phase 2 study combining venetoclax with R-CHOP was 800mg on cycle 1, days 4-10 and cycle 2-8, days 1-10. Dose finding for venetoclax plus G-CHOP dose finding is ongoing, according to the investigators, who will present their latest findings during the ASCO meeting.
Hackensack University Medical Center Partners with CNOW to Launch Innovative Telehealth Pilot
Oct 7 15
CNOW announced strategic partnership with Hackensack University Medical Center. CNOW's telehealth solutions will effectively allow HackensackUMC's medical staff to connect with patients receiving psychiatric care through real-time, interactive video visits in the hospital, to the home, or anywhere services need to be delivered at any time.
John Theurer Cancer Center Joins Study Exploring Novel Delivery of Cancer-Selective Gene Therapy to Treat Brain Cancer
Mar 18 15
Physicians at the John Theurer Cancer Center (JTCC) at Hackensack University Medical Center announced their involvement in a promising multicenter Phase 1 study assessing the safety and tolerability of Toca 511 in patients with glioblastoma, the most common and lethal form of brain cancer. Toca 511 is a retroviral replicating vector that has been engineered to deliver a therapeutic gene selectively to brain tumor cells while sparing healthy brain tissue. In this study, sponsored by Tocagen Inc., Toca 511 is injected directly into the brain tumor through a stereotactic biopsy needle. Once injected, Toca 511 infects tumor cells, sparing healthy functioning brain cells. During the following weeks, patients are then given cycles of an oral medication, 5-flucytosine (5-FC), an antifungal drug that readily enters the brain. The infected tumor cells now carry genetic instructions for an enzyme that converts 5-FC into 5-fluorouracil (5-FU), a highly-potent chemotherapy that destroys cancer cells, which may lead to activation of the immune system against the tumor. Currently ongoing, the study will enroll up to 50 patients with glioblastoma and other aggressive high-grade gliomas (Grade 3 or 4) who have already undergone surgery, radiation therapy and chemotherapy. Among the estimated 13,000 new cases of high-grade glioma each year in the United States, glioblastoma is the most common and aggressive, with only 5% of patients surviving to five years after diagnosis.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|